Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 19, Issue 11, Pages 1481-1493
Publisher
Oxford University Press (OUP)
Online
2017-03-18
DOI
10.1093/neuonc/nox052
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT® nanoparticle formulation against non-small-cell lung cancer brain metastases
- (2016) Maria Sambade et al. Nanomedicine
- Clinical implications of molecular heterogeneity in triple negative breast cancer
- (2015) Brian D. Lehmann et al. BREAST
- Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer
- (2015) O. Karginova et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- MEK and PI3K inhibition in solid tumors: rationale and evidence to date
- (2015) E. Jokinen et al. Therapeutic Advances in Medical Oncology
- Can we unlock the potential of IGF-1R inhibition in cancer therapy?
- (2014) Helen King et al. CANCER TREATMENT REVIEWS
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers
- (2014) K Mahajan et al. ONCOGENE
- Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis
- (2014) Bodour Salhia et al. PLoS One
- The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer
- (2014) Sara Jansson et al. PLoS One
- Human breast cancer metastases to the brain display GABAergic properties in the neural niche
- (2014) J. Neman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pazopanib Inhibits the Activation of PDGFRβ-Expressing Astrocytes in the Brain Metastatic Microenvironment of Breast Cancer Cells
- (2013) Brunilde Gril et al. AMERICAN JOURNAL OF PATHOLOGY
- Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes
- (2013) Aleix Prat et al. BREAST CANCER RESEARCH AND TREATMENT
- Protein Kinase C α Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells
- (2013) Wai Leong Tam et al. CANCER CELL
- Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials
- (2013) Matteo Santoni et al. INTERNATIONAL JOURNAL OF CANCER
- MEK1/2 Inhibition Suppresses Tamoxifen Toxicity on CNS Glial Progenitor Cells
- (2013) H.-Y. Chen et al. JOURNAL OF NEUROSCIENCE
- MicroRNA 9-3p Targets 1 Integrin To Sensitize Claudin-Low Breast Cancer Cells to MEK Inhibition
- (2013) J. S. Zawistowski et al. MOLECULAR AND CELLULAR BIOLOGY
- Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
- (2013) Carey K. Anders et al. PLoS One
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
- (2012) P. J. Roberts et al. CLINICAL CANCER RESEARCH
- Pazopanib for the treatment of breast cancer
- (2012) Laleh Amiri-Kordestani et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
- (2012) Maja J. A. de Jonge et al. INVESTIGATIONAL NEW DRUGS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
- (2011) J. Chuck Harrell et al. BREAST CANCER RESEARCH AND TREATMENT
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
- (2011) J. Jing et al. MOLECULAR CANCER THERAPEUTICS
- Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
- (2011) Kunal S. Taskar et al. PHARMACEUTICAL RESEARCH
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis
- (2010) B. Gril et al. CLINICAL CANCER RESEARCH
- Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
- (2010) P. R. Lockman et al. CLINICAL CANCER RESEARCH
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
- (2010) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT)
- (2009) A. Niwinska et al. ANNALS OF ONCOLOGY
- Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
- (2009) O. K. Mirzoeva et al. CANCER RESEARCH
- Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
- (2009) Carey K. Anders et al. Clinical Breast Cancer
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer
- (2008) Nancy U. Lin et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started